Indegene announced a 17% year-over-year revenue growth for the quarter ending September 30, 2025, achieving revenues of INR 8,042 million. The company also expanded its capabilities through the acquisitions of BioPharm, a US-based marketing services agency, and WARN & CO., a UK-based transformation consulting firm. Adjusted EBITDA margin stood at 18.2%, while profit margin reached 12.7%.
Financial Performance Highlights
Indegene reported strong financial results for the quarter ended September 30, 2025. Key highlights include:
- Revenue from operations: INR 8,042 million, a 17.1% increase year-over-year.
- Adjusted EBITDA: INR 1,461 million.
- Adjusted EBITDA margin: 18.2%.
- Profit after tax: INR 1,021 million.
- Profit margin: 12.7%.
These figures showcase the company’s continued growth and profitability within the life sciences sector. This reflects a 5.7% growth compared to the previous quarter.
Strategic Acquisitions
Indegene has strategically acquired two companies to enhance its service offerings:
- BioPharm: A US-based specialized marketing services agency, part of the Omnicom Health Group, which has expertise in omnichannel strategy.
- WARN & CO.: A UK-based transformation consulting firm specializing in operating model design and transition.
These acquisitions are expected to strengthen Indegene’s capabilities and align with its future direction. They add advanced service lines and expertise to better serve a broader range of client needs. This will enable Indegene to expand its capabilities through two strategic acquisitions.
Management Commentary
Manish Gupta, Chairman and CEO of Indegene, stated that the company delivered strong growth for the fourth consecutive quarter. He also expressed excitement about welcoming BioPharm and WARN & Co. to the Indegene family. Suhas Prabhu, CFO, highlighted the company’s focus on executing strategic priorities, from business development to M&A, in Q2FY26.
Source: BSE